CounterACT Researchers & Projects

CounterACT Researchers & Projects

Countermeasures against chemical threats banner


CounterACT sites on U.S. map


Abstracts, budgets, and contact information for all CounterACT-supported  projects are available via the NIH RePORTER database

Jump to: U54, U01, R21, SBIR


Research Centers of Excellence (U54)

UAB Research Center of Excellence in Arsenicals
Mohammad Athar, PhD
University of Alabama at Birmingham
U54ES030246

UMDNJ/Rutgers University CounterACT Research Center of Excellence 
Jeffrey D. Laskin, PhD
RBHS-School of Public Health
U54AR055073

Novel Anticonvulsant and Neuroprotective Therapies for TETS and OP Intoxication 
Pamela J. Lein, PhD
University of California, Davis
U54NS079202

Advancing Novel Cyanide Countermeasures
Calum MacRae, MD, PhD
Brigham and Women's Hospital
Randall T. Peterson, PhD
University of Utah
U54NS112107

Development of Antidotes for Toxic Gases
Carl W. White, MD
University of Colorado, Denver
U54ES027698

 


Individual Research Projects (U01)

Dexamethasone as an Effective Therapy for Ocular Injuries by Vesicating Agents
Rajesh Agarwal, PhD
University of Colorado, Denver
U01EY030405

Extracellular RNA as Therapeutic Target After Toxic Chemical Inhalation
Aftab Ahmad, PhD
University of Alabama, Birmingham
U01ES025069

Blocking Arsenicals-induced Cutaneous Injury
Mohammad Athar, PhD
University of Alabama, Birmingham
U01NS095678

Identification of Lead Compounds to Topically Treat Sulfur Mustard Injury to Reduce Ocular Damage and Improve Vision 
Shenda Baker, PhD
Synedgen, Inc.
U01EY030406

Development of the Vitamin B12 Analog Cobinamide as a Hydrogen Sulfide Antidote 
Gerry R. Boss, MD
University of California, San Diego
U01NS087964

Sodium Tetrathionate as a Cyanide Antidote 
Gerry R. Boss, MD 
University of California, San Diego
U01NS105057

Antiglutamatergic Therapy to Protect the Immature Brain Against Nerve Agents 
Maria F.M. Braga, DDS, PhD
Henry M Jackson Foundation for the Advancement of Military Medicine
U01NS102135

Antidotes Against HCI-induced Chronic Lung Injury
John D. Catravas, PhD
Old Dominion University
U01ES030674

Identification of Novel Brain-Penetrating Phenoxyalkyl Pyridinium Oxime Countermeasures
Janice E. Chambers, PhD
Mississippi State University
U01NS107127

Optimization of AEOL10150 Treatment of Sulfur Mustard-Induced Lung Toxidrome in a Pig Model 
Brian J. Day, PhD  
National Jewish Health
U01ES029430

Novel Counteract Agents to Reduce Mortality and Morbidity Following Organophosphate Status Epilepticus 
Robert J. DeLorenzo, MPH, MD, PhD
Virginia Commonwealth University
U01NS105058

Neurosteroids as a Standard Medical Countermeasure for OP Poisoning 
Kelvin W. Gee, PhD    
University of California, Irvine
U01NS102131

Improved Therapeutics for the Resurrection of the Aged Form of  Acetylcholinesterase 
Christopher Hadad, PhD    
Ohio State University
U01NS112101

Cucurbituril Type Receptors as Sequestration Agents for Drugs of Abuse
Lyle D. Isaacs, PhD
University of Maryland, College Park
R01GM132345

Immunotherapy to Counteract Lethal Doses of Carfentanil
Kim Janda, PhD
Scripps Research Institute
U01DA046323

Advanced TRPA1 Inhibitor for the Treatment of Chlorine Inhalation Injury
Sven-Eric Jordt, PhD
Duke University
U01ES030672

TIE2 Activation for the Treatment of Chemical-induced Acute Lung Injury
Christopher D. Kontos, PhD
Duke University
U01ES028187

Advanced Development of Drugs to Mitigate Parathion Intoxication
Jeffrey D. Laskin, PhD
RBHS-School of Public Health
U01NS108956

Functional Genomics of Chemical-induced Acute Lung Injury 
George D. Leikauf, PhD    
University of Pittsburgh, Pittsburgh
U01ES015675

Optimization of Novel Thioesters as a Therapeutic Strategy for Combating Opioid Overdoses and Abuse 
Stephen J. Lewis, PhD    
Case Western Reserve University
U01DA051373

Translation of Novel and Repurposed Drugs to Address the Acute and Late Effects of Mustard Exposure 
Kurt Lu, MD
Northwestern University, Chicago 
U01AR071168

Bromine Inhalation Induced Lung Injury: Novel Mechanisms and Treatment Strategies
Sadis Matalon, PhD
University of Alabama, Birmingham
U01ES026458

CIALIS® Reverses Halogen Induced Injury to Pregnant Animals and Their Offspring
Sadis Matalon, PhD
University of Alabama, Birmingham
U01ES027697

Turbo Eye Drops to Treat Ocular Toxicity and Blindness from Sulfur Mustard
Rajiv R. Mohan, PhD
University of Missouri, Columbia
U01EY031650

Optimization of a Combined Drug and Delivery Device for Treatment of Cyanide Poisoning
Steven E. Patterson, PhD
University of Minnesota
U01NS112125

Cyanide/Azide Detoxification by New Cobalt Complexes and NO Donors
James Peterson, PhD
University of Pittsburgh at Pittsburgh
U01NS109793

Antibody-based Countermeasures Against Fentanyl and its Analogues
Marco Pravetoni, PhD
University of Minnesota
U01DA051658

Novel Pediatric Anticonvulsants for Nerve Agents
Doodipala S. Reddy, PhD
Texas A&M University Health Science Center
U01NS117209

Development of IM Formulation of (2S,3S)-SPD for Nerve Agent Seizures
Michael A. Rogawski, MD, PhD
University of California, Davis
U01NS112102

Targeted Therapeutic Approaches to Counteract Toxicity from Phosgene Oxime Skin Exposure
Neera Tewari-Singh, PhD
Michigan State University
U01AR075470

Molecular Imaging of Chemical Threats and Countermeasures
Charles M. Thompson, PhD
University of Montana
U01NS092495

Novel Antibody-Oxime Pairing to Reduce Circulating Organophosphate Levels
Charles M. Thompson, PhD
Human Biomolecular Research Institute
U01NS112108

Anticholinergic and Antiepileptic Therapies for Chlorine Toxicity
Livia A. Veress, MD
University of Colorado, Denver
U01NS102101

 


Small Business Innovation Research (SBIR)

Development of a Field-Deployable Device to Rapidly Measure Blood Cyanide Levels
Hans Boehringer, PhD
Diagnostic Consulting Network, Inc.
R44NS076359

Cyanalyzer a Medical Laboratory Device for the Rapid Diagnosis of Cyanide Exposure 
Randy Jackson, PhD
Seacoast Science, Inc.
R44NS097066

 


Exploratory/Developmental Projects (R21)

Examining Novel Fentalogs: Pharmacological Characteristics and Reversibility
Jessica P. Anand, PhD
University of Michigan, Ann Arbor
R03DA048129

Specialized Pro-resolving Mediators as Potential Medical Countermeasures in a Pig Model of Chlorine Gas-induced Acute Lung Injury
Satyanarayana Achanta, PhD
Duke University
R21ES030331

MicroRNAs in Skin Inflammation and Wounding by Mustard Vesicants
Rajesh Agarwal, PhD
University of Colorado, Denver
R21AR074929

Novel Therapeutic Targets for Fluoroacetate-induced Toxicities
Aftab Ahmad, PhD
University of Alabama at Birmingham
R21ES032353

Airway Stem Cell Activation in the Mitigation of Halogen-induced Lung Injury
Shama Ahmad, PhD
University of Alabama at Birmingham
R21ES030525

Covalent Naloxone Nanoparticles for Next Generation Fentanyl Countermeasures
Saadyah Averick, PhD
Allegheny-Singer Research Institute
R21DA050565

Antidotes Against Mustard-Induced Chronic Lung Injury
John D. Catravas, PhD
Old Dominion University
R21ES030528

Identification of Novel Brain-Penetrating Oxime Antidotes for Phorate Toxicity
Janice E. Chambers, PhD
Mississippi State University
R21NS108954

Chlorinated Lipid Modification of Proteins: Biomarkers of Chlorine Gas Exposure
David A. Ford, PhD
Saint Louis University
R21ES031562

The Cyclic Redox Dye Azure B as a Novel Cyanide Antidote: In Vivo Efficacy Studies
Philippe Haouzi, MD, PhD
Pennsylvania State University Hershey Medical Center
R21NS110549

Novel Antidotes for H2S Poisoning 
Fumito Ichinose, PhD   
Massachusetts General Hospital
R21NS11667

Soman-induced neuropathology in Gottingen minipig: large animal model assessment for MCM 
Lucy Lange, PhD    
Geneva Foundation
R21NS110556

Identifying Molecular Targets for the Proconvulsant Activity of TETS 
Pamela J. Lein, PhD
University of California, Davis
R21NS110647

Formulation and Encapsulation of Enzyme Countermeasures Against Organophosphorus Compounds
Thomas J. Magliery, PhD
Ohio State University
R21NS084899

Nanomedicine Approach to Counteract Acrolein-Induced Blindness and Toxicity to the Eye
Rajiv R. Mohan, PhD
University of Missouri-Columbia
R21EY030233

Turbo Eye Drops to Treat Ocular Toxicity and Blindness from Sulfur Mustard
Rajiv R. Mohan, PhD
University of Missouri-Columbia
R21EY030234

Computationally Designed Stable Artificial Phosphotriesterases for Detoxification of Organophosphorus Agents
Jin K. Montclare, PhD
New York University
R21NS103831

Microneedles for Emergency Treatment of Synthetic Opioid Overdose
Roger J. Narayan, MD, PhD
North Carolina State University, Raleigh
R21DA040916

Phosgene Oxime Cutaneous Toxicity and Mechanisms to Identify Therapeutic Targets
Neera Tewari-Singh, PhD
University of Colorado, Denver
R21AR073544

Saracatinib Mitigates OP nerve agent-induced Long-term Neurotoxicity
Thimmasettappa Thippeswamy, PhD
Iowa State University
R21NS110648

Imaging the Healing of Ocular Injury Caused by Vesicants to Identify New Therapies
Roy Wollman, PhD
University of California, Los Angeles
R21EY031283

 


Contracts, Inter-Agency Agreements, and Other Resources

CounterACT Preclinical Development Facility (CPDF) 
Carol Green, PhD, DABT
SRI International
N01NS62369


Interagency Agreements (IAAs) between the National Institutes of Health and the Department of Defense
Chemicals Affecting Skin, Eyes & Mucous Membranes - Toxic Vesicants and Industrial Chemicals
Chemicals Affecting the Nervous System - Anticonvulsants and Neuroprotectants
Cyanide Diagnostics and Efficacy Testing of Next Generation Cyanide Antidotes
Chemicals Affecting the Respiratory Tract - Pulmonary Toxicants
James F. Dillman, PhD

U.S. Army Medical Research Institute of Chemical Defense